Analysts Are Bullish on These Healthcare Stocks: Stryker (SYK), Solid Biosciences (SLDB)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Stryker (SYK) and Solid Biosciences (SLDB) with bullish sentiments.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Stryker (SYK)
Citi analyst Joanne Wuensch maintained a Buy rating on Stryker today and set a price target of $385.00. The company’s shares closed last Tuesday at $345.88.
According to TipRanks.com, Wuensch is a 3-star analyst with an average return of
Currently, the analyst consensus on Stryker is a Strong Buy with an average price target of $425.10, implying a 22.2% upside from current levels. In a report issued on April 13, Leerink Partners also initiated coverage with a Buy rating on the stock with a $410.00 price target.
See today’s best-performing stocks on TipRanks >>
Solid Biosciences (SLDB)
In a report released today, Gil Blum from Needham maintained a Buy rating on Solid Biosciences, with a price target of $19.00. The company’s shares closed last Tuesday at $8.23.
According to TipRanks.com, Blum is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Solid Biosciences with a $17.86 average price target.
Read More on SYK:
Disclaimer & DisclosureReport an Issue
- Nike downgraded, Starbucks upgraded: Wall Street’s top analyst calls
- Stryker to acquire Amplitude Vascular Systems, terms undisclosed
- Stryker price target lowered to $397 from $412 at BTIG
- Stryker initiated with an Outperform at Leerink
- William Blair med tech analyst holds an analyst/industry conference call
